Gepirone in the treatment of major depression
Gepirone is a serotonin (5-hydroxytryptamine, 5-HT) type1A receptor agonist and a pharmacologic analogue of buspirone. Two double-blind, placebo-controlled studies show the efficacy of gepirone in the treatment of major depression. Study 1 demonstrates gepirone's superiority over placebo in an...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical psychopharmacology 1990-06, Vol.10 (3), p.77S-85S |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 85S |
|---|---|
| container_issue | 3 |
| container_start_page | 77S |
| container_title | Journal of clinical psychopharmacology |
| container_volume | 10 |
| creator | JENKINS, S. W ROBINSON, D. S FABRE, L. F ANDARY, J. J MESSINA, M. E REICH, L. A |
| description | Gepirone is a serotonin (5-hydroxytryptamine, 5-HT) type1A receptor agonist and a pharmacologic analogue of buspirone. Two double-blind, placebo-controlled studies show the efficacy of gepirone in the treatment of major depression. Study 1 demonstrates gepirone's superiority over placebo in an 8-week acute treatment of patients with major depression, including the melancholic subtype. Gepirone's antidepressant dose range is tentatively established at 5-30 mg/day. Study 2 reveals the benefit of gepirone compared with placebo in 4-week continuation therapy of patients with major depression who initially responded to 6 weeks of open therapy with gepirone. Analysis of Hamilton Rating Scale for Depression item scores show gepirone especially improves scores on items of core depression. |
| doi_str_mv | 10.1097/00004714-199006001-00014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79901700</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79901700</sourcerecordid><originalsourceid>FETCH-LOGICAL-c255t-bf6343e7eb7c5c2a0c504ede8379b6809b7cef2873ae440abdd802c41a460043</originalsourceid><addsrcrecordid>eNpNkMtOwzAQRS0EKqHwCUjewM4wfqSOl6iCglSJTRfsLMeZiFR5YacL_h6XlsdsRpp7Z0b3EEI53HEw-h5SKc0V48YALAA4SxOuTkjGcymZ5uLtlGQgdBK0MufkIsbt3qFFPiMzbrQ0SmSErXBswtAjbXo6vSOdArqpw36iQ007tx0CrXAMGGMz9JfkrHZtxKtjn5PN0-Nm-czWr6uX5cOaeZHnEyvrhVQSNZba51448DkorLCQ2pSLAkyaYy0KLR0qBa6sqgKEV9ypFEXJObk9nB3D8LHDONmuiR7b1vU47KLVKTTXAMlYHIw-DDEGrO0Yms6FT8vB7kHZH1D2F5T9BpVWr48_dmWH1d_igUzSb466i961dXC9b-I_m4IUwMgvV6lvNQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79901700</pqid></control><display><type>article</type><title>Gepirone in the treatment of major depression</title><source>Journals@Ovid Ovid Autoload</source><source>MEDLINE</source><creator>JENKINS, S. W ; ROBINSON, D. S ; FABRE, L. F ; ANDARY, J. J ; MESSINA, M. E ; REICH, L. A</creator><creatorcontrib>JENKINS, S. W ; ROBINSON, D. S ; FABRE, L. F ; ANDARY, J. J ; MESSINA, M. E ; REICH, L. A</creatorcontrib><description>Gepirone is a serotonin (5-hydroxytryptamine, 5-HT) type1A receptor agonist and a pharmacologic analogue of buspirone. Two double-blind, placebo-controlled studies show the efficacy of gepirone in the treatment of major depression. Study 1 demonstrates gepirone's superiority over placebo in an 8-week acute treatment of patients with major depression, including the melancholic subtype. Gepirone's antidepressant dose range is tentatively established at 5-30 mg/day. Study 2 reveals the benefit of gepirone compared with placebo in 4-week continuation therapy of patients with major depression who initially responded to 6 weeks of open therapy with gepirone. Analysis of Hamilton Rating Scale for Depression item scores show gepirone especially improves scores on items of core depression.</description><identifier>ISSN: 0271-0749</identifier><identifier>EISSN: 1533-712X</identifier><identifier>DOI: 10.1097/00004714-199006001-00014</identifier><identifier>PMID: 1973942</identifier><identifier>CODEN: JCPYDR</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Aged ; Anti-Anxiety Agents ; Biological and medical sciences ; Depressive Disorder - drug therapy ; Depressive Disorder - psychology ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Administration Schedule ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychiatric Status Rating Scales ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Pyrimidines - administration & dosage ; Randomized Controlled Trials as Topic</subject><ispartof>Journal of clinical psychopharmacology, 1990-06, Vol.10 (3), p.77S-85S</ispartof><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c255t-bf6343e7eb7c5c2a0c504ede8379b6809b7cef2873ae440abdd802c41a460043</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,23909,23910,25118,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19402879$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1973942$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JENKINS, S. W</creatorcontrib><creatorcontrib>ROBINSON, D. S</creatorcontrib><creatorcontrib>FABRE, L. F</creatorcontrib><creatorcontrib>ANDARY, J. J</creatorcontrib><creatorcontrib>MESSINA, M. E</creatorcontrib><creatorcontrib>REICH, L. A</creatorcontrib><title>Gepirone in the treatment of major depression</title><title>Journal of clinical psychopharmacology</title><addtitle>J Clin Psychopharmacol</addtitle><description>Gepirone is a serotonin (5-hydroxytryptamine, 5-HT) type1A receptor agonist and a pharmacologic analogue of buspirone. Two double-blind, placebo-controlled studies show the efficacy of gepirone in the treatment of major depression. Study 1 demonstrates gepirone's superiority over placebo in an 8-week acute treatment of patients with major depression, including the melancholic subtype. Gepirone's antidepressant dose range is tentatively established at 5-30 mg/day. Study 2 reveals the benefit of gepirone compared with placebo in 4-week continuation therapy of patients with major depression who initially responded to 6 weeks of open therapy with gepirone. Analysis of Hamilton Rating Scale for Depression item scores show gepirone especially improves scores on items of core depression.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Anxiety Agents</subject><subject>Biological and medical sciences</subject><subject>Depressive Disorder - drug therapy</subject><subject>Depressive Disorder - psychology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Pyrimidines - administration & dosage</subject><subject>Randomized Controlled Trials as Topic</subject><issn>0271-0749</issn><issn>1533-712X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkMtOwzAQRS0EKqHwCUjewM4wfqSOl6iCglSJTRfsLMeZiFR5YacL_h6XlsdsRpp7Z0b3EEI53HEw-h5SKc0V48YALAA4SxOuTkjGcymZ5uLtlGQgdBK0MufkIsbt3qFFPiMzbrQ0SmSErXBswtAjbXo6vSOdArqpw36iQ007tx0CrXAMGGMz9JfkrHZtxKtjn5PN0-Nm-czWr6uX5cOaeZHnEyvrhVQSNZba51448DkorLCQ2pSLAkyaYy0KLR0qBa6sqgKEV9ypFEXJObk9nB3D8LHDONmuiR7b1vU47KLVKTTXAMlYHIw-DDEGrO0Yms6FT8vB7kHZH1D2F5T9BpVWr48_dmWH1d_igUzSb466i961dXC9b-I_m4IUwMgvV6lvNQ</recordid><startdate>199006</startdate><enddate>199006</enddate><creator>JENKINS, S. W</creator><creator>ROBINSON, D. S</creator><creator>FABRE, L. F</creator><creator>ANDARY, J. J</creator><creator>MESSINA, M. E</creator><creator>REICH, L. A</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199006</creationdate><title>Gepirone in the treatment of major depression</title><author>JENKINS, S. W ; ROBINSON, D. S ; FABRE, L. F ; ANDARY, J. J ; MESSINA, M. E ; REICH, L. A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c255t-bf6343e7eb7c5c2a0c504ede8379b6809b7cef2873ae440abdd802c41a460043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Anxiety Agents</topic><topic>Biological and medical sciences</topic><topic>Depressive Disorder - drug therapy</topic><topic>Depressive Disorder - psychology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Pyrimidines - administration & dosage</topic><topic>Randomized Controlled Trials as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JENKINS, S. W</creatorcontrib><creatorcontrib>ROBINSON, D. S</creatorcontrib><creatorcontrib>FABRE, L. F</creatorcontrib><creatorcontrib>ANDARY, J. J</creatorcontrib><creatorcontrib>MESSINA, M. E</creatorcontrib><creatorcontrib>REICH, L. A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JENKINS, S. W</au><au>ROBINSON, D. S</au><au>FABRE, L. F</au><au>ANDARY, J. J</au><au>MESSINA, M. E</au><au>REICH, L. A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gepirone in the treatment of major depression</atitle><jtitle>Journal of clinical psychopharmacology</jtitle><addtitle>J Clin Psychopharmacol</addtitle><date>1990-06</date><risdate>1990</risdate><volume>10</volume><issue>3</issue><spage>77S</spage><epage>85S</epage><pages>77S-85S</pages><issn>0271-0749</issn><eissn>1533-712X</eissn><coden>JCPYDR</coden><abstract>Gepirone is a serotonin (5-hydroxytryptamine, 5-HT) type1A receptor agonist and a pharmacologic analogue of buspirone. Two double-blind, placebo-controlled studies show the efficacy of gepirone in the treatment of major depression. Study 1 demonstrates gepirone's superiority over placebo in an 8-week acute treatment of patients with major depression, including the melancholic subtype. Gepirone's antidepressant dose range is tentatively established at 5-30 mg/day. Study 2 reveals the benefit of gepirone compared with placebo in 4-week continuation therapy of patients with major depression who initially responded to 6 weeks of open therapy with gepirone. Analysis of Hamilton Rating Scale for Depression item scores show gepirone especially improves scores on items of core depression.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>1973942</pmid><doi>10.1097/00004714-199006001-00014</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0271-0749 |
| ispartof | Journal of clinical psychopharmacology, 1990-06, Vol.10 (3), p.77S-85S |
| issn | 0271-0749 1533-712X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79901700 |
| source | Journals@Ovid Ovid Autoload; MEDLINE |
| subjects | Adult Aged Anti-Anxiety Agents Biological and medical sciences Depressive Disorder - drug therapy Depressive Disorder - psychology Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Humans Male Medical sciences Middle Aged Neuropharmacology Pharmacology. Drug treatments Psychiatric Status Rating Scales Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Pyrimidines - administration & dosage Randomized Controlled Trials as Topic |
| title | Gepirone in the treatment of major depression |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T14%3A12%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gepirone%20in%20the%20treatment%20of%20major%20depression&rft.jtitle=Journal%20of%20clinical%20psychopharmacology&rft.au=JENKINS,%20S.%20W&rft.date=1990-06&rft.volume=10&rft.issue=3&rft.spage=77S&rft.epage=85S&rft.pages=77S-85S&rft.issn=0271-0749&rft.eissn=1533-712X&rft.coden=JCPYDR&rft_id=info:doi/10.1097/00004714-199006001-00014&rft_dat=%3Cproquest_cross%3E79901700%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79901700&rft_id=info:pmid/1973942&rfr_iscdi=true |